Jamal Mahmud, MD
Psychiatry · Hammonton, NJNPI 1396983532
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,800 of the $14,443 with a category attached, or 74.8%. AbbVie accounts for 90.6% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $13,105 and has fallen 91.5% since, to $1,111 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $244.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Neuronetics, Inc.$1K
- Alkermes, Inc.$75
- Sunovion Pharmaceuticals Inc.$38
- Axsome Therapeutics, Inc.$37
- Neurocrine Biosciences, Inc.$32
- plus $64 from 3 others
What the payments were for
- Speaking & faculty fees$10,80075%
- Travel & lodging$2,18915%
- Food & beverage$1,45010%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $13,086 |
| Neuronetics, Inc. | 4 | $1,111 |
| Alkermes, Inc. | 2 | $75 |
| Sunovion Pharmaceuticals Inc. | 4 | $38 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$12,566
- NEUROSTAR TMS THERAPY SYSTEM$1,111
How this compares
$14,443 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 11 | $28,474 |
| Aripiprazole | 39 | $13,690 |
| Chlorpromazine Hcl | 116 | $13,372 |
| Olanzapine OdtOlanzapine | 77 | $7,266 |
| Risperidone OdtRisperidone | 28 | $3,867 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $3,454 |
| Haloperidol Lactate | 21 | $3,439 |
| Risperidone | 51 | $3,142 |
| Valproic AcidValproic Acid (As Sodium Salt) | 21 | $1,690 |
| Fluphenazine Hcl | 36 | $850 |
| Clozapine | 26 | $663 |
| Mirtazapine | 24 | $614 |
| Clonazepam | 46 | $381 |
| Trazodone Hcl | 21 | $308 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $306 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Hammonton
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
- Anthony RostainCamden$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.